Skip to main content
Clinical Trials/NCT01159691
NCT01159691
Completed
Not Applicable

A Multicentric, Non-interventional Study on Switching From Oral Parkinson Therapy to Neupro® in Patients With Idiopathic Parkinson's Disease With Gastrointestinal Symptoms

UCB Pharma GmbH21 sites in 1 country76 target enrollmentJune 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Parkinson's Disease
Sponsor
UCB Pharma GmbH
Enrollment
76
Locations
21
Primary Endpoint
Change From Baseline to Visit 3 in the Assessment of Intensity of Gastrointestinal (GI) Complaints for Any Reason as Per Visual Analogue Scale (VAS)
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions after changing treatment to Neupro® transdermal patch in patients suffering from idiopathic Parkinson´s Disease with gastrointestinal symptoms while being treated with oral antiparkinson drugs. The objective of the study is to ascertain whether switching therapy to Neupro® transdermal patch can provide any relief in gastrointestinal symptoms.

Detailed Description

Routine treatment as per approved label in Europe in accordance with the terms of the local marketing authorization for Neupro®.

Registry
clinicaltrials.gov
Start Date
June 2010
End Date
March 2012
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The decision to prescribe Neupro® must have been made by the physician before and independently of his/her decision to include the patient in the study
  • The patient's treatment must be in accordance with the terms of the local marketing authorization (MA) for Neupro®
  • The patient must have a diagnosis of Idiopathic Parkinson's disease
  • The patient must have signed the Consent form regarding study information, data transfer and use
  • Patient suffering from gastrointestinal symptoms while being treated with oral Parkinson's medication

Exclusion Criteria

  • Not applicable

Outcomes

Primary Outcomes

Change From Baseline to Visit 3 in the Assessment of Intensity of Gastrointestinal (GI) Complaints for Any Reason as Per Visual Analogue Scale (VAS)

Time Frame: From Baseline to Visit 3 (approximately 6 weeks)

Patients were asked to classify the intensity of their GI complaints on a scale ranging from 0 (no complaints) to 100 (extremely severe complaints). Negative values indicate an improvement from Baseline to Visit 3 with larger negative values showing a better improvement.

Change From Baseline to Visit 3 in the Sum Score of Gastrointestinal (GI) Complaints

Time Frame: From Baseline to Visit 3 (approximately 6 weeks)

Sum score of GI complaints was calculated from frequency and intensity of the complaints. The intensity of GI complaints during the last week ranges from 0 (no complaints) to 3 (severe) and the frequency of these complaints during the last week ranges from 0 (never) to 4 (every day). For each of the seven GI complaints assessed at a visit (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, and diarrhea), intensity and frequency were multiplied to achieve individual item scores of GI complaints (range: 0 - 12). Finally, the sum score of GI complaints per visit was calculated by accumulating 6 of the 7 item scores (excluding swallowing disorders, which was recorded at Baseline only) for patients with valid values in each score (range: 0 - 72). Negative values indicate an improvement from Baseline to Visit 3 with larger negative values showing a better improvement.

Assessment of Patient Satisfaction Referring to Gastrointestinal (GI) Complaints Following Treatment Switch to Neupro® at Visit 2

Time Frame: At Visit 2 (after approximately 2-4 weeks)

Patient satisfaction referring to GI complaints is classified into 5 categories: * Missing * Very satisfied * Satisfied * Moderately satisfied * Not satisfied.

Assessment of Patient Satisfaction Referring to Gastrointestinal (GI) Complaints Following Treatment Switch to Neupro® at Visit 3

Time Frame: At Visit 3 (after approximately 6 weeks)

Patient satisfaction referring to GI complaints is classified into 5 categories: * Missing * Very satisfied * Satisfied * Moderately satisfied * Not satisfied.

Study Sites (21)

Loading locations...

Similar Trials